No to Scottish independence, but firms now face other uncertainties
This article was originally published in Scrip
Now that Scotland has voted against independence, there will no big debates over separate drug pricing systems, no discussion over who would regulate medicines north of the border, no uncertainty over patents, medical research funding or the many other areas of medicine and healthcare that would have been affected by the break-up of the UK.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.